Intellia Therapeutics

Intellia Therapeutics

World Rank (Aug-2026)
7030
Market Cap (Aug-2026)
1.669 Billion USD
Market Cap (Mar-08-2026)
1.588 Billion USD
World Rank (Jan-05-2024)
4,779
Market Cap (Jan-05-2024)
2.644 Billion USD
World Rank (Jul-30-2023)
3,722
Market Cap (Jul-30-2023)
3.734 Billion USD
World Rank (Jan-07-2022)
2,284
Market Cap (Jan-07-2022)
7.869 Billion USD
World Rank (Jan-01-2021)
3,873
Market Cap (Jan-01-2021)
3.514 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
NTLA
Employee Count
312
Employee Count as of Date
As on 2021
Headquarters City/State
Massachusetts
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
68 Million USD
Annual Operating Income in USD
-441 Million USD
Annual Net Income in USD
-413 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
842 Million USD
Total Liabilities in USD
171 Million USD
Total Equity in USD
671 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Technology
HealthCare Products
Company Website
INTELLIA THERAPEUTICS
Wikipedia
Wikipedia
Yahoo
Yahoo @ Nasdaq
Company Profile

Intellia Therapeutics is a Biotechnology company. The company annual revenue is 43.2 million USD, total assets is 334.2 million USD and 211 employees as on 2019. The headquarters is in USA.

Annual Results Summary

INTELLIA THERAPEUTICS - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-202252-458 (Loss)-474 (Loss)
Dec-202133-267 (Loss)-267 (Loss)
Dec-202057-136 (Loss)-134 (Loss)
Dec-201943-106 (Loss)-99 (Loss)
Dec-20183090 (Loss)-85 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 1,520 Million USD.

Total Liabilities as on Dec-2022 was 284 Million USD.

Total Equity as on Dec-2022 was 1,235 Million USD.

Founded Year
2014
IPO Year
2016
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances

Share